People who like to waste time either won't or can't engage in the discussion so they attempt to discredit the other guy or change the subject or introduce little nothings that have no bearing. I really don't have time for that.
Won't discuss it? That is a LIE.
Meg asked for "a" study.
I posted dozens of studies, including reviews by the Institute of Medicine (IOM), National Academy of Science, and the University of California Center for Medical Cannabis Research, et al.
Meg looked at the titles and somehow channeled that the studies focused on benefits and not enough on "side-effects." —complete manure. The IOM admitted their bias was against MJ, but like the AMA, was forced by the evidence to support medical MJ.
You, on the other hand stated that your "experience" was more important than the studies.
How is anyone supposed to have a rational discussion with anyone, like the $%^& rabbis, who just waves his/her hand and discards the evidence?
Worse, you and Meg both, like $%^&* rabbis, used a standard that you would apply apply against MJ ("sober") that you would not apply against alcohol. Double-standard.
Called on that, like you, Meg invoked her "experience" and her charism of reading the interior disposition of MJ users, as proving her "opinions."
What a joke, both of you, like a pair of $%^&* rabbis.
To write a series of 8 articles, I spent almost a year reviewing the peer-reviewed literature and that changed my previous opposition to MJ. Once again, here's my bibliography from that work.
It is current to 2011. Because the evidence was so solid, I have had no need to re-visit the literature for a deep-dive.
*******
Important reviews
University of California Center for Medical Cannabis Research—2010 Report to the Legislature
http://www.cmcr.ucsd.edu/images/pdfs/CMCR_REPORT_FEB17.pdf Review on clinical studies with cannabis and cannabinoids 2005-2009. Hazecamp A and Grotenhermen F. Cannabinoids 2010;5(special issue):1-21.
www.cannabis-med.org/data/pdf/en_2010_01_special.pdf Cannabinoids in medicine: A review of their therapeutic potential. Amar MB. Journal of Ethnopharmacology 105 (2006) 1–25.
http://www.ucla.edu.ve/dmedicin/departamentos/fisiologia/cannabinoidsRevPatologias.pdf Emerging Clinical Applications for Cannabis and Cannabinoids: A Review of the Recent Scientific Literature, 2000 – 2010. Armentano P. NORML Foundation, Washington DC 2010.
http://norml.org/pdf_files/NORML_Clinical_Applications_for_Cannabis_and_Cannabinoids.pdf Marijuana and Medicine: Assessing the Science Base. National Academy of Science Institute of Medicine, 1999
http://www.nap.edu/openbook.php?record_id=6376 popularized in: Marijuana As Medicine? – The Science Behind the Controversy. Mack A and Joy J. National Academy of Science. National Academy Press, Washington DC 2000.
http://books.nap.edu/openbook.php?record_id=9586&page=R1 AIDS/HIV
University of California Center for Medical Cannabis Research—2010 Report to the Legislature
http://www.cmcr.ucsd.edu/images/pdfs/CMCR_REPORT_FEB17.pdfHuman Immunodeficiency Virus (HIV)
http://www.norml.org/index.cfm?Group_ID=7485 “Marijuana and AIDS” in Marijuana As Medicine? – The Science Behind the Controversy. Mack A and Joy J. National Academy of Science. National Academy Press, Washington DC 2000.
http://books.nap.edu/openbook.php?record_id=9586&page=86 ALS (Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease)
Amyotrophic Lateral Sclerosis (ALS)
http://www.norml.org/index.cfm?Group_ID=7004 Alzheimer's Disease
Alzheimer's Disease
http://norml.org/index.cfm?Group_ID=7003 Cachexia. Wasting syndrome
See sections 3.1 and 3.2 of Cannabinoids in medicine: A review of their therapeutic potential. Amar MB. Journal of Ethnopharmacology 105 (2006) 1–25.
http://www.ucla.edu.ve/dmedicin/departamentos/fisiologia/cannabinoidsRevPatologias.pdf Cancer
Gliomas/Cancer
http://www.norml.org/index.cfm?Group_ID=7008 “Marijuana and Cancer” in Marijuana As Medicine? – The Science Behind the Controversy. Mack A and Joy J. National Academy of Science. National Academy Press, Washington DC 2000.
http://books.nap.edu/openbook.php?record_id=9586&page=95 Cannabis and Cannabinoids (PDQ®). National Cancer Institute. 2011.
http://www.cancer.gov/cancertopics/pdq/cam/cannabis/healthprofessional/page1 Cardiovascular disease
The Potential for Clinical Use of Cannabinoids in Treatment
of Cardiovascular Diseases. Durst R and Lotan C. Cardiovascular Therapeutics 2011 Feb;29(1):17-22. doi: 10.1111/j.1755-5922.2010.00233.x. Epub 2010 Oct 14.
http://www.ncbi.nlm.nih.gov/pubmed/20946323 The emerging role of the endocannabinoid system in cardiovascular disease. Pacher P, Steffens S. Semin Immunopathol. 2009 Jun;31(1):63-77. Epub 2009 Apr 9.
http://www.springerlink.com/content/a04103g160h16450/fulltext.pdf Cannabinoid receptors in atherosclerosis. Steffens S, Mach F. Curr Opin Lipidol. 2006 Oct;17(5):519-26.
http://journals.lww.com/co-lipidology/Abstract/2006/10000/Cannabinoid_receptors_in_atherosclerosis.5.aspx Cannabinoid receptors in acute and chronic complications of atherosclerosis. Mach F, Montecucco F, Steffens S. Br J Pharmacol. 2008 January; 153(2): 290–298.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219535/pdf/0707517a.pdf Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Pacher P, Haskó G. Br J Pharmacol. 2008 Jan;153(2):252-62. Epub 2007 Nov 19.
http://onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0707582/pdf The role of the endocannabinoid system in atherosclerosis. Mach F, Steffens S. J Neuroendocrinol. 2008 May;20 Suppl 1:53-7.
http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2826.2008.01685.x/pdf Cardiovascular Effects of Cannabis | Medicinal Cannabis Information. Independent Drug Monitoring Unit, United Kingdom, undated
http://www.idmu.co.uk/canncardio.htm Crohns Disease
Gastrointestinal Disorders
http://www.norml.org/index.cfm?Group_ID=7009 Endocannabinoid sysytem
The Endocannabinoid System as an Emerging Target of Pharmacotherapy. National Institute of Health: Pacher P, Bátkai S, Kunos G. Pharmacol Rev. 2006 Sep;58(3):389-462.
http://pharmrev.aspetjournals.org/content/58/3/389.full.pdf Endocrine disease, diabetes
The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. Endocr Rev. 2006 Feb;27(1):73-100. Epub 2005 Nov 23.
http://fk.uwks.ac.id/elib/Arsip/Departemen/Biokimia/The%20Emerging%20Role%20of%20the%20Endocannabinoid%20System.pdf Fibromyalgia
Nabilone for the Treatment of Pain in Fibromyalgia. Skrabek RQ, Galimova L, Ethans K, Perry D. J Pain. 2008 Feb;9(2):164-73. Epub 2007 Nov 5.
http://docs.google.com/viewer?a=v&q=cache:9gDyCVhqJSMJ:files.meetup.com/404848/2008_Nabilone-for-the-Treatment-of-Pain-in-Fibromyalgia.pdf+Nabilone+for+the+Treatment+of+Pain+in+Fibromyalgia&hl=en&gl=us&pid=bl&srcid=ADGEESjFGavzxEJkBjsOj_YyWPHuo5PRG034PLna8X6n3sXGT696PVuaEH15HF07xVpfV10wLPfon8-nZoD0RcJfU6LInnuqHOGpKDECN4oQ6OWBgGgwXWckH2QB31FTn1BZn0KX9U7A&sig=AHIEtbQlDN8uMzxJIm6KKL0POTJdhmbsvg Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. Curr Med Res Opin. 2006 Jul;22(7):1269-76.
http://www.ncbi.nlm.nih.gov/pubmed/16834825 Fibromyalgia
http://norml.org/index.cfm?Group_ID=7007 Glaucoma
American Glaucoma Society position statement: Marijuana and the treatment of glaucoma. American Glaucoma Society, Prepared by Henry Jampel, M.D., M.H.S., August 10, 2009
http://www.americanglaucomasociety.net/associations/5224/files/Marijuana%20and%20Glaucoma%20august%2030_BOD%20Approved%2010.23.09.pdf Marijuana and Glaucoma” in Marijuana As Medicine? – The Science Behind the Controversy. Mack A and Joy J. National Academy of Science. National Academy Press, Washington DC 2000.
http://books.nap.edu/openbook.php?record_id=9586&page=124 Hepatitis C
Hepatitis C
http://www.norml.org/index.cfm?Group_ID=7010 Marijuana effects, drug levels, DUI
Marijuana effect and delta9-tetrahydrocannabinol plasma level. Chiang CWN and Barnett G. Clinical Pharmacology and Therapeutics 1984 Aug;36(2):234-8.
http://www.ncbi.nlm.nih.gov/pubmed/6086207 Contact highs and urinary cannabinoids excretion after passive exposure to marijuana smoke. Cone EJ and Johnson RE. Clinical Pharmacology and Therapeutics 1986 Sep;40(3):247-56.
http://www.ncbi.nlm.nih.gov/pubmed/3017628 Do delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Karschner EL, Schwilke EW, Lowe RH, Darwin WD, Pope HG, Herning R, Cadet JL, Huestis MA. Addiction. 2009 Dec;104(12):2041-8. Epub 2009 Oct 5.
http://www.clinchem.org/cgi/reprint/49/7/1114 Developing limits for driving under cannabis. Grotenhermen F, Leson G, Berghaus G, Drummer OH, Krüger HP, Longo M, Moskowitz H, Perrine B, Ramaekers JG, Smiley A, Tunbridge R. Addiction 2007 Dec;102(12):1910-7. Epub 2007 Oct 4.
http://www.ncbi.nlm.nih.gov/pubmed/17916224 Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. Gustafson RA, Levine B, Stout PR, Klette KL, George MP, Moolchan ET, Huestis MA. Clin Chem. 2003 Jul;49(7):1114-24.
http://www.ncbi.nlm.nih.gov/pubmed/12816908 Editorial: Practical Challenges to Positive Drug Tests for Marijuana. ElSohly MA. Clin Chem. 2003 Jul;49(7):1037-8.
http://www.clinchem.org/cgi/reprint/49/7/1037 Dose related risk of motor vehicle crashes after cannabis use. Ramaekers JG, Berghaus G, van Laar M, Drummer OH. Drug Alcohol Depend. 2004 Feb 7;73(2):109-19.
http://www.ukcia.org/research/DoseRelatedRiskOfCrashes.pdf Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Ramaekers JG, Theunissen EL, de Brouwer M, Toennes SW, Moeller MR, Kauert G. Psychopharmacology (Berl). 2011 Mar;214(2):391-401. Epub 2010 Oct 30.
http://www.cannabistherapyinstitute.com/bills/dui/raemakers.etal.pdf Cannabis and Driving: A Scientific and Rational Review. Armentano P. NORML Foundation, Washington DC 2010
http://norml.org/index.cfm?Group_ID=7459 Sex differences in the effects of marijuana on simulated driving performance. Anderson BM, Rizzo M, Block RI, Pearlson GD, O'Leary DS. J Psychoactive Drugs. 2010 Mar;42(1):19-30.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033009/ Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, Cassuto Y, Shinar D. Accid Anal Prev. 2008 May;40(3):926-34. Epub 2007 Nov 26.
http://www.ncbi.nlm.nih.gov/pubmed/18460360 Muscle Spasms
Dystonia
http://www.norml.org/index.cfm?Group_ID=7006 “Marijuana and Muscle Spasticity” in Marijuana As Medicine? – The Science Behind the Controversy. Mack A and Joy J. National Academy of Science. National Academy Press, Washington DC 2000.
http://books.nap.edu/openbook.php?record_id=9586&page=106 Nausea
See sections 3.1 of Cannabinoids in medicine: A review of their therapeutic potential. Amar MB. Journal of Ethnopharmacology 105 (2006) 1–25.
http://www.ucla.edu.ve/dmedicin/departamentos/fisiologia/cannabinoidsRevPatologias.pdf Pain
University of California Center for Medical Cannabis Research—2010 Report to the Legislature
http://www.cmcr.ucsd.edu/images/pdfs/CMCR_REPORT_FEB17.pdfChronic Pain
http://www.norml.org/index.cfm?Group_ID=7786 “Marijuana and Pain” in Marijuana As Medicine? – The Science Behind the Controversy. Mack A and Joy J. National Academy of Science. National Academy Press, Washington DC 2000.
http://books.nap.edu/openbook.php?record_id=9586&page=77# Post traumatic Stress Disorder
Cannabinoid receptor activation in the basolateral amygdala blocks the effects of stress on the conditioning and extinction of inhibitory avoidance. Ganon-Elazar E, Akirav I. J Neurosci. 2009 Sep 9;29(36):11078-88.
http://www.jneurosci.org/content/29/36/11078.full.pdf+html [Extinction of emotional response as a novel approach of pharmacotherapy of anxiety disorders]. Lehner M, Wisłowska-Stanek A, Płaznik A. Psychiatr Pol. 2009 Nov-Dec;43(6):639-53.
http://www.ncbi.nlm.nih.gov/pubmed/20209877 The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD). Fraser GA. CNS Neurosci Ther. 2009 Winter;15(1):84-8.
http://onlinelibrary.wiley.com/doi/10.1111/j.1755-5949.2008.00071.x/pdf Public policy
Harm reduction-the cannabis paradox. Melamede R. Harm Reduct J. 2005 Sep 22;2:17.
http://www.harmreductionjournal.com/content/pdf/1477-7517-2-17.pdf Seizures
See sections 3.7 of Cannabinoids in medicine: A review of their therapeutic potential. Amar MB. Journal of Ethnopharmacology 105 (2006) 1–25.
http://www.ucla.edu.ve/dmedicin/departamentos/fisiologia/cannabinoidsRevPatologias.pdf “Marijuana and Neurological Disorders” in Marijuana As Medicine? – The Science Behind the Controversy. Mack A and Joy J. National Academy of Science. National Academy Press, Washington DC 2000.
http://books.nap.edu/openbook.php?record_id=9586&page=115